In GLP-1 RA trials, Hispanic/Latino representation was highest in “Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome (ELIXA)” at 29.1% and lowest in “Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL)” at 7.6% (26, 30) (Figure 1B). Here, GLP1R is linked to type 2 diabetes mellitus.